Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 8/20 | 0.42 |
| ▸ | PDE4A | P27815 | 5/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.42 |
| ▸ | HTR1B | P28222 | 2/20 | 0.42 |
| ▸ | GCGR | P47871 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4693296 | 0.79 | CYP1A2 (0.35) | PDE4DHTR1BHTR7KDM4EMEN1 | |
| SCHEMBL4694471 | 0.77 | CYP1A2 (0.34) | PDE4DHTR1BHTR7KDM4EMEN1 | |
| Trifenagrel SCHEMBL31058836 | 0.74 | MEN1 (0.63) | GCGRHTR7KDM4EMEN1POLB | |
| Trifenagrel SCHEMBL4428157 | 0.74 | MEN1 (0.63) | GCGRHTR7KDM4EMEN1POLB | |
| SCHEMBL4695663 | 0.74 | CHRM2 (0.35) | PDE4DHTR7KDM4EMEN1KMT2A | |
| Trifenagrel SCHEMBL11078277 | 0.74 | MEN1 (0.62) | GCGRHTR7KDM4EMEN1POLB | |
| SCHEMBL4692954 | 0.72 | BCHE (0.36) | PDE4DKDM4EMEN1KMT2AHRH1 | |
| SCHEMBL4694104 | 0.72 | SIGMAR1 (0.33) | MEN1KMT2AHRH1 | |
| SCHEMBL22181937 | 0.71 | CHEK2 (0.53) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4695791 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1684749-B1 | USE OF 1,3-DIAZA-DIBENZO[e,h] AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | GLAXOSMITHKLINE ZAGREB (HR) | 2007-09-05 | — | — | EP | disclosed |
| US-20070129330-A1 | 1,3-Diaza-dibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129330-A1 | 1,3-Diaza-dibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders | DBH, BCHE, DDT | PDE5A 545/4885PDE4A 636/4885PDE4B 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.